Anti-Mouse CD1d Antibody (1B1)
Anti-Mouse CD1d Antibody (1B1) is an antibody targeting mouse CD1d (Kd=12.5 nM). By inserting into the lipid-binding groove of CD1d, Anti-Mouse CD1d Antibody (1B1) overlaps with the binding sites of type I and type II NKT cell receptors (TCR), thereby effectively blocking TCR-mediated interactions. Anti-Mouse CD1d Antibody (1B1) activates antigen-presenting cells such as dendritic cells and macrophages, induces them to release IL-12p70, and increases the levels of key cytokines including IL-12, IFN-γ and IFN-α in mouse serum. Anti-Mouse CD1d Antibody (1B1) can be used in studies related to renal cancer, breast cancer and colon adenocarcinoma. When combined with anti-DR5 or anti-CD137 antibodies and chemotherapeutic drugs, Anti-Mouse CD1d Antibody (1B1) exhibits significant tumor inhibitory and even eradication effects in mice.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Rat IgG2b
Mouse
|
CD1d 12.5 nM (Kd) |
Anti-Mouse CD1d Antibody (1B1) (overnight) binds to insect cell-expressed mouse CD1d presenting endogenous lipid, sulfatide, or GT1b with similar affinity, with Kd values ranging from 10.2 to 12.6 nM[2].
Anti-Mouse CD1d Antibody (1B1) (2 h, overnight) blocks Type I NKT 1.2 and Type II NKT XV19 hybridoma activation by α-GalCer and sulfatide, respectively, but does not block activation by α-GSA[26,P5p]; 1B1 IgG blocks activation of both hybridomas by all three tested glycolipids, including α-GSA[26,P5p], at concentrations as low as 1.5 μg/mL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1DMab therapy with Anti-Mouse CD1d Antibody (1B1) (i.p.; 200 μg; 3 administrations) efficiently eliminates established 4T1 breast cancer in BALB/c mice, and remains effective even when administration is delayed until the tumors reach a large volume; this therapy is completely dependent on CD8+ T cells and IFN-γ, independent of type I NKT cells, and only partially dependent on NK cells and IL-12[1].
1DMab therapy with Anti-Mouse CD1d Antibody (1B1) (200 μg; intraperitoneal injection; 3 administrations) effectively eliminates established CT26L5 colon adenocarcinoma in BALB/c mice. This effect is completely dependent on CD8+ T cells and IFN-γ, independent of type I NKT cells or NK cells, and only partially dependent on IL-12[1].
The 1DMab therapy with Anti-Mouse CD1d Antibody (1B1) (200 μg; i.p.; administered 3 times on days 19, 23, and 27) exhibits better efficacy than the combination therapy of Doxorubicin (HY-15142A) + anti-CD1d + anti-CD137 in eradicating established late-stage 4T1 breast cancer in BALB/c mice[1].
1DMab therapy with Anti-Mouse CD1d Antibody (1B1) (i.p.; 200 μg; administered 3 times on days 19, 23 and 27) exhibits superior efficacy over the combination therapy of Gemcitabine (HY-17026) + anti-CD1d + anti-CD137 and other tested chemoimmunotherapies in eliminating established advanced CT26L5 colon adenocarcinoma in BALB/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c wild-type; BALB/c Jα18−/−; BALB/c CD1d−/− (female, >6 weeks old, subcutaneous inoculation with R331 renal carcinoma cells)[1]
-
Dosage:12.5-400 μg (dose-dependent tumor eradication); 200 μg (delayed treatment; cell depletion; cytokine neutralization)
-
Administration:i.p.; 3 doses on days 7,11,15; 3 doses on days 11,15,19; 3 doses on days 15,19,23; 3 doses on days 19,23,27
-
Result:Resulted in 40% tumor eradication when 200 μg treatment delayed to day 11, 20% when delayed to day 15, and 0% cures (only tumor growth suppression) when delayed to day 19.
Completely lost tumor suppressive activity (0% cures) with 200 μg in CD8+ T cell-depleted mice.
Suppressed tumor growth but resulted in 0% cures with 200 μg in NK cell-depleted mice.
Failed to suppress tumor growth (0% cures) with 200 μg in CD1d−/− mice.
Resulted in 0% cures with 200 μg in mice treated with neutralizing anti-IFN-γ or anti-IL-12 mAbs.
-
Animal Model:BALB/c wild-type; BALB/c Jα18−/− (female, >6 weeks old, subcutaneous inoculation with CT26L5 colon carcinoma cells)[1]
-
Dosage:200 μg
-
Administration:i.p.; 3 doses on days 7,11,15; 3 doses on days 15,19,23; 3 doses on days 19,23,27; 3 doses on days 27,31,35
-
Result:Completely lost tumor suppressive activity (0% cures) in CD8+ T cell-depleted mice or mice treated with neutralizing anti-IFN-γ mAbs.
Suppressed tumor growth and maintained 60% (3/5) tumor eradication in NK cell-depleted mice.
Suppressed tumor growth with 20% tumor eradication in mice treated with neutralizing anti-IL-12 mAbs.
Induced 100% tumor eradication in Jα18−/− mice (lacking type I NKT cells), comparable to wild-type mice.
CD1d
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay, Research in vivo
Chemical Information
-
SMILES
[Anti-Mouse CD1d Antibody (1B1)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Teng MW, et al. CD1d-based combination therapy eradicates established tumors in mice. J Immunol. 2009 Aug 1;183(3):1911-20. [Content Brief]
[2]. Ying G, et al. Structural basis of NKT cell inhibition using the T-cell receptor-blocking anti-CD1d antibody 1B1. J Biol Chem. 2019 Aug 30;294(35):12947-12956. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse CD1d Antibody (1B1) Related Classifications
HY-P992059 Related Classifications
Powered by Bioz